Raloxifene, a cannabinoid type-2 receptor inverse agonist, mitigates visual deficits and pathology and modulates microglia after ocular blast.
Sign Up to like & getrecommendations! Published in 2022 at "Experimental eye research"
DOI: 10.1016/j.exer.2022.108966
Abstract: Visual deficits after ocular blast injury (OBI) are common, but pharmacological approaches to improve long-term outcomes have not been identified. Blast forces frequently damage the retina and optic nerves, and work on experimental animals has… read more here.
Keywords: raloxifene; optic nerve; pathology; visual deficits ... See more keywords